S. Neelakantan

发表

Population Pharmacokinetic Analysis of Recombinant Factor VIII Fc Fusion Protein in Subjects With Severe Hemophilia A: Expanded to Include Pediatric Subjects

Lei Diao, S. Katragadda, S. Neelakantan, 2021, Journal of clinical pharmacology.

Recombinant factor VIII Fc fusion protein for the prevention and treatment of bleeding in children with severe hemophilia A

J. Mahlangu, R. Liesner, B. Nolan, 2015, Journal of thrombosis and haemostasis : JTH.

Bronchoscopic assessment of airway retention time of aerosolized xylitol

J. Zabner, J. L. Watt, M. Allaman, 2006, Respiratory research.

Evaluation of the safety, pharmacokinetics, and efficacy of recombinant factor VIII fc fusion protein in Japanese subjects with severe haemophilia A: analysis from the A-LONG study

T. Matsushita, K. Nogami, M. Taki, 2016 .

Erythropoietin pharmacokinetic/pharmacodynamic analysis suggests higher doses in treating neonatal anemia

J. Widness, P. Veng‐Pedersen, R. Schmidt, 2009, Pediatrics international : official journal of the Japan Pediatric Society.

Population pharmacokinetics of recombinant factor VIII Fc fusion protein

I. Nestorov, M. Rogge, T. Ludden, 2015, Clinical pharmacology in drug development.

Recombinant factor VIII Fc fusion protein: extended‐interval dosing maintains low bleeding rates and correlates with von Willebrand factor levels

J. Dumont, I. Nestorov, D. Quon, 2014, Journal of thrombosis and haemostasis : JTH.

Phase 3 study of recombinant factor VIII Fc fusion protein in severe hemophilia A.

J. Dumont, I. Nestorov, D. Perry, 2014, Blood.

Safety, Efficacy, and Pharmacokinetics of Recombinant Factor VIII FC Fusion Protein (RFVIIIFC) in Previously Treated Paediatric Subjects with Severe Haemophilia A (Kids A-LONG)

J. Mahlangu, B. Nolan, G. Young, 2013 .

Safety, Efficacy, and Pharmacokinetics of Recombinant Factor VIII Fc Fusion Protein (rFVIIIFc) in Previously-Treated Children with Severe Hemophilia a (Kids-ALONG)

J. Mahlangu, B. Nolan, G. Young, 2014 .

286 EXPOSURE-RESPONSE RELATIONSHIP OF FILIBUVIR IN HCV INFECTED PATIENTS: APPLICATION TO DOSE SELECTION FOR COMBINATION THERAPY

T. Tensfeldt, M. O’Gorman, J. Hammond, 2010 .

Antiviral activity of the hepatitis C virus polymerase inhibitor filibuvir in genotype 1–infected patients

P. Troke, J. Hammond, F. Wagner, 2011, Hepatology.

Anti-TL1A Antibody PF-06480605 Safety and Efficacy for Ulcerative Colitis: A Phase 2a Single-Arm Study [102/120 characters including spaces].

E. Peeva, S. Danese, K. Hung, 2021, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

Safety, Tolerability, and Pharmacokinetics of PF‐06823859, an Anti–Interferon β Monoclonal Antibody: A Randomized, Phase I, Single‐ and Multiple‐Ascending‐Dose Study

Dean M. Messing, S. Tarabar, K. Page, 2020, Clinical pharmacology in drug development.

Dystrophin and mini-dystrophin quantification by mass spectrometry in skeletal muscle for gene therapy development in Duchenne muscular dystrophy

H. Neubert, M. Binks, J. Palandra, 2021, Gene Therapy.

Disease progression modeling of the North Star Ambulatory Assessment for Duchenne Muscular Dystrophy

L. Harnisch, P. Jayachandran, S. Neelakantan, 2023, CPT: pharmacometrics & systems pharmacology.

Antitumor Necrosis Factor-like Ligand 1A Therapy Targets Tissue Inflammation and Fibrosis Pathways and Reduces Gut Pathobionts in Ulcerative Colitis

Zhan Ye, M. Baniecki, S. Danese, 2021, Inflammatory bowel diseases.

Association between Confidence in Smiling and Esthetic Characteristics: A Cross-sectional Study in Chengalpattu

S. Neelakantan, Prabhu Subramani, S. Johnson, 2021, Journal of Scientific Dentistry.

A ‘bottom‐up’ approach for endo‐PK/PD analysis

J. Widness, P. Veng‐Pedersen, R. Schmidt, 2006, Biopharmaceutics & drug disposition.

Determination of drug absorption rate in time‐variant disposition by direct deconvolution using beta clearance correction and end‐constrained non‐parametric regression

P. Veng‐Pedersen, S. Neelakantan, 2005, Biopharmaceutics & drug disposition.

Population pharmacokinetics of recombinant factor VIII Fc fusion protein

S. Neelakantan, Shuanglian Li, Thomas M. Ludden, 2015, Clinical pharmacology in drug development.